The ChiNext ETF (E Fund) (159915) had an average daily turnover of 3.951 billion yuan over the past month, ranking first in its category.

As of 10:53, the Hang Seng Stock Connect Innovative Drug Index (HSSCID) fell 1.43%. Among the top ten constituent stocks by weight, Akeso Biopharma rose 0.87%, CSPC Pharmaceutical Group fell 3.64%, BeiGene fell 1.98%, Sino Biopharmaceutical fell 0.98%, Innovent Biologics fell 1.35%, Hansoh Pharmaceutical fell 0.6%, 3SBio fell 0.8%, Kelun-Biotech fell 2.01%, China Medical System fell 0.71%, and Ascentage Pharma-B fell 1.31%. As of April 16, the Hang Seng Stock Connect Innovative Drug Index has risen 59.13% over the past year.

The E Fund Hang Seng Stock Connect Innovative Drug ETF (159316) tracks the Hang Seng Stock Connect Innovative Drug Index. This fund is highly favored by capital, attracting over 280 million yuan in net inflows in the past 5 days. As of the previous trading day, the fund's average daily turnover in the past month was 750 million yuan, indicating active trading and strong liquidity. As of press time, the E Fund Hang Seng Stock Connect Innovative Drug ETF (159316) received a net subscription of 76 million units during the trading session.

On the news front, BeiGene recently released its 2025 annual report, achieving annual operating revenue of 38.225 billion yuan, a year-on-year increase of 40.46%; it achieved net profit attributable to the parent company of 1.461 billion yuan, turning a profit. In the same period of 2024, the company incurred a loss of 4.978 billion yuan. This marks the first full-year profit since its listing.

Industrial Securities stated that China's innovative drug sector possesses development advantages of high efficiency and low cost, and holds competitive advantages in hot technology fields such as ADC, bispecific antibodies, and small nucleic acids, which is expected to continue demonstrating industry competitiveness. On the domestic policy front, comprehensive encouragement of innovation across the entire chain is expected to drive overall improvement in the domestic business model for innovative drugs, with particular attention to the advancement of diversified payment systems. Looking ahead, while the outbound business development (BD) of innovative drugs continues to accelerate, BD products are expected to reflect the acceleration of overseas product advancement, further enhancing the potential peak sales and success rates of products, thereby expanding the overall sector's potential.

The management fee rate for the E Fund Hang Seng Stock Connect Innovative Drug ETF (159316) is 0.15%, the custody fee rate is 0.05%, and the total expense ratio is 0.2%. The relatively low fees can effectively reduce cost expenditures for investors.

The E Fund Hang Seng Stock Connect Innovative Drug ETF (159316) is currently the only ETF product in the market tracking the Hang Seng Innovative Drug Index, offering high elasticity and scarcity, helping investors better seize the current investment opportunities in Hong Kong-listed innovative drug stocks.